GSK lifts long-term outlook amid RSV sales and new drugs

Meanwhile, Novo Nordisk said sales and profit will surge again this year as it continues to roll out its blockbuster obesity shot Wegovy around the world.

Chief executive Emma Walmsley is working to revamp GSK’s pipeline after abandoning brands like Centrum and Panadol in the spinoff of the consumer-health division. Pic: JEAN-PIERRE MULLER/AFP/Getty Images

GSK upgraded its long-term outlook boosted by sales of the pharmaceutical company’s new RSV vaccine and other drug launches.

The drugmaker now expects to generate more than £38bn (€44.5bn) of sales by 2031, up from a previous forecast of £33bn It also said sales should rise by more than 7% on a compounded annual growth rate between 2021 and 2026 with adjusted operating profit rising more than 11%.